Lipoprotein(a) and risk-weighted apolipoprotein B: a novel metric for atherogenic risk.
Apolipoprotein B
Atherosclerotic cardiovascular disease
Coronary heart disease
Lipoprotein(a)
Novel metric
Risk assessment
Journal
Lipids in health and disease
ISSN: 1476-511X
Titre abrégé: Lipids Health Dis
Pays: England
ID NLM: 101147696
Informations de publication
Date de publication:
27 Sep 2024
27 Sep 2024
Historique:
received:
29
06
2024
accepted:
17
09
2024
medline:
28
9
2024
pubmed:
28
9
2024
entrez:
28
9
2024
Statut:
epublish
Résumé
Retention of apolipoprotein B (apoB)-containing lipoproteins within the arterial wall plays a major causal role in atherosclerotic cardiovascular disease (ASCVD). There is a single apoB molecule in all apoB-containing lipoproteins. Therefore, quantitation of apoB directly estimates the number of atherogenic particles in plasma. ApoB is the preferred measurement to refine the estimate of ASCVD risk. Low-density lipoprotein (LDL) particles are by far the most abundant apoB-containing particles. In patients with elevated lipoprotein(a) (Lp(a)), apoB may considerably underestimate risk because Mendelian randomization studies have shown that the atherogenicity of Lp(a) is approximately 7-fold greater than that of LDL on a per apoB particle basis. In subjects with increased Lp(a), the association between LDL-cholesterol and incident CHD (coronary heart disease) is increased, but the association between apoB and incident CHD is diminished or even lost. Thus, there is a need to understand the mechanisms of Lp(a), LDL-cholesterol and apoB-related CHD risk and to provide clinicians with a simple practical tool to address these complex and variable relationships. How can we understand a patient's overall lipid-driven atherogenic risk? What proportion of this risk does apoB capture? What proportion of this risk do Lp(a) particles carry? To answer these questions, we created a novel metric of atherogenic risk: risk-weighted apolipoprotein B. In nmol/L: Risk-weighted apoB = apoB - Lp(a) + Lp(a) x 7 = apoB + Lp(a) x 6. Proportion of risk captured by apoB = apoB divided by risk-weighted apoB. Proportion of risk carried by Lp(a) = Lp(a) × 7 divided by risk-weighted apoB. Risk-weighted apoB agrees with risk estimation from large epidemiological studies and from several Mendelian randomization studies. ApoB considerably underestimates risk in individuals with high Lp(a) levels. The association between apoB and incident CHD is diminished or even lost. These phenomena can be overcome and explained by risk-weighted apoB.
Sections du résumé
BACKGROUND
BACKGROUND
Retention of apolipoprotein B (apoB)-containing lipoproteins within the arterial wall plays a major causal role in atherosclerotic cardiovascular disease (ASCVD). There is a single apoB molecule in all apoB-containing lipoproteins. Therefore, quantitation of apoB directly estimates the number of atherogenic particles in plasma. ApoB is the preferred measurement to refine the estimate of ASCVD risk. Low-density lipoprotein (LDL) particles are by far the most abundant apoB-containing particles. In patients with elevated lipoprotein(a) (Lp(a)), apoB may considerably underestimate risk because Mendelian randomization studies have shown that the atherogenicity of Lp(a) is approximately 7-fold greater than that of LDL on a per apoB particle basis. In subjects with increased Lp(a), the association between LDL-cholesterol and incident CHD (coronary heart disease) is increased, but the association between apoB and incident CHD is diminished or even lost. Thus, there is a need to understand the mechanisms of Lp(a), LDL-cholesterol and apoB-related CHD risk and to provide clinicians with a simple practical tool to address these complex and variable relationships. How can we understand a patient's overall lipid-driven atherogenic risk? What proportion of this risk does apoB capture? What proportion of this risk do Lp(a) particles carry? To answer these questions, we created a novel metric of atherogenic risk: risk-weighted apolipoprotein B.
METHODS
METHODS
In nmol/L: Risk-weighted apoB = apoB - Lp(a) + Lp(a) x 7 = apoB + Lp(a) x 6. Proportion of risk captured by apoB = apoB divided by risk-weighted apoB. Proportion of risk carried by Lp(a) = Lp(a) × 7 divided by risk-weighted apoB.
RESULTS
RESULTS
Risk-weighted apoB agrees with risk estimation from large epidemiological studies and from several Mendelian randomization studies.
CONCLUSIONS
CONCLUSIONS
ApoB considerably underestimates risk in individuals with high Lp(a) levels. The association between apoB and incident CHD is diminished or even lost. These phenomena can be overcome and explained by risk-weighted apoB.
Identifiants
pubmed: 39334349
doi: 10.1186/s12944-024-02307-6
pii: 10.1186/s12944-024-02307-6
doi:
Substances chimiques
Lipoprotein(a)
0
Apolipoproteins B
0
Cholesterol, LDL
0
APOB protein, human
0
Apolipoprotein B-100
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
316Informations de copyright
© 2024. The Author(s).
Références
Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111–88. https://doi.org/10.1093/eurheartj/ehz455 .
doi: 10.1093/eurheartj/ehz455
pubmed: 31504418
Glavinovic T, Thanassoulis G, de Graaf J, Couture P, Hegele RA, Sniderman AD. Physiological bases for the superiority of apolipoprotein B over low-density lipoprotein cholesterol and Non-high-density Lipoprotein Cholesterol as a marker of Cardiovascular Risk. J Am Heart Assoc. 2022;11:e025858. https://doi.org/10.1161/JAHA.122.025858 .
doi: 10.1161/JAHA.122.025858
pubmed: 36216435
pmcid: 9673669
Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European atherosclerosis society consensus statement. Eur Heart J. 2022;43:3925–46. https://doi.org/10.1093/eurheartj/ehac361 .
doi: 10.1093/eurheartj/ehac361
pubmed: 36036785
pmcid: 9639807
Björnson E, Adiels M, Taskinen M-R, Burgess S, Chapman MJ, Packard CJ, et al. Lipoprotein(a) is markedly more atherogenic than LDL: an apolipoprotein B-Based genetic analysis. J Am Coll Cardiol. 2024;83:385–95. https://doi.org/10.1016/j.jacc.2023.10.039 .
doi: 10.1016/j.jacc.2023.10.039
pubmed: 38233012
Arnold N, Blaum C, Goßling A, Brunner FJ, Bay B, Zeller T, et al. Impact of lipoprotein(a) level on low-density lipoprotein cholesterol- or apolipoprotein B-Related risk of Coronary Heart Disease. J Am Coll Cardiol. 2024;84:165–77. https://doi.org/10.1016/j.jacc.2024.04.050 .
doi: 10.1016/j.jacc.2024.04.050
pubmed: 38960510
Yang CY, Lee FS, Chan L, Sparrow DA, Sparrow JT, Gotto AM. Determination of the molecular mass of apolipoprotein B-100. A chemical approach. Biochem J. 1986;239:777–80. https://doi.org/10.1042/bj2390777 .
doi: 10.1042/bj2390777
pubmed: 3827828
pmcid: 1147355
Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 2015;12:e1001779. https://doi.org/10.1371/journal.pmed.1001779 .
doi: 10.1371/journal.pmed.1001779
pubmed: 25826379
pmcid: 4380465
Burgess S, Ference BA, Staley JR, Freitag DF, Mason AM, Nielsen SF, et al. Association of LPA variants with Risk of Coronary Disease and the implications for lipoprotein(a)-Lowering therapies: a mendelian randomization analysis. JAMA Cardiol. 2018;3:619–27. https://doi.org/10.1001/jamacardio.2018.1470 .
doi: 10.1001/jamacardio.2018.1470
pubmed: 29926099
pmcid: 6481553
Zheng W, Chilazi M, Park J, Sathiyakumar V, Donato LJ, Meeusen JW, et al. Assessing the Accuracy of estimated lipoprotein(a) cholesterol and lipoprotein(a)-Free low-density lipoprotein cholesterol. J Am Heart Assoc. 2022;11:e023136. https://doi.org/10.1161/JAHA.121.023136 .
doi: 10.1161/JAHA.121.023136
pubmed: 35023348
pmcid: 9238537
Langlois MR, Chapman MJ, Cobbaert C, Mora S, Remaley AT, Ros E, et al. Quantifying atherogenic lipoproteins: current and future challenges in the era of Personalized Medicine and very low concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM. Clin Chem. 2018;64:1006–33. https://doi.org/10.1373/clinchem.2018.287037 .
doi: 10.1373/clinchem.2018.287037
pubmed: 29760220
Tsimikas S, Gordts PLSM, Nora C, Yeang C, Witztum JL. Statin therapy increases lipoprotein(a) levels. Eur Heart J. 2020;41:2275–84. https://doi.org/10.1093/eurheartj/ehz310 .
doi: 10.1093/eurheartj/ehz310
pubmed: 31111151
Colantonio LD, Bittner V, Safford MM, Marcovina S, Brown TM, Jackson EA, et al. Lipoprotein(a) and the risk for Coronary Heart Disease and ischemic stroke events among black and white adults with Cardiovascular Disease. J Am Heart Assoc. 2022;11:e025397. https://doi.org/10.1161/JAHA.121.025397 .
doi: 10.1161/JAHA.121.025397
pubmed: 35621195
pmcid: 9238745
Ference BA, Kastelein JJP, Ray KK, Ginsberg HN, Chapman MJ, Packard CJ, et al. Association of Triglyceride-Lowering LPL variants and LDL-C-Lowering LDLR variants with risk of Coronary Heart Disease. JAMA. 2019;321:364–73. https://doi.org/10.1001/jama.2018.20045 .
doi: 10.1001/jama.2018.20045
pubmed: 30694319
pmcid: 6439767
Björnson E, Adiels M, Taskinen M-R, Burgess S, Rawshani A, Borén J, et al. Triglyceride-rich lipoprotein remnants, low-density lipoproteins, and risk of coronary heart disease: a UK Biobank study. Eur Heart J. 2023;44:4186–95. https://doi.org/10.1093/eurheartj/ehad337 .
doi: 10.1093/eurheartj/ehad337
pubmed: 37358553
pmcid: 10576615
O’Donoghue ML, Fazio S, Giugliano RP, Stroes ESG, Kanevsky E, Gouni-Berthold I, et al. Lipoprotein(a), PCSK9 inhibition, and Cardiovascular Risk. Circulation. 2019;139:1483–92. https://doi.org/10.1161/CIRCULATIONAHA.118.037184 .
doi: 10.1161/CIRCULATIONAHA.118.037184
pubmed: 30586750